LUCAR-G79D T cells
Phase 1Biologic
LUCAR-G79D T cells is one of 38 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Ocrevus
RochePhase 3
Gazyva
RochePhase 3
Intrarosa
Alnylam PharmaceuticalsPhase 3
Depo-Provera
Eli LillyPhase 3
Cellcept
NovartisPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Benadryl
PParkedale
Phase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Imuran
LLegacy Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LUCAR-G79D T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- NNanjing Legend Biotech Co.